Risk of Subsequent Breast Cancer in Women with Early Stage HER2-Positive Breast Cancer in a Large Community Health Plan

Overview

Journal Breast Cancer (Dove Med Press)

Publisher Dove Medical Press

Date 2023 Aug 22

PMID 37605715

Authors

Reina Haque

Lie Hong Chen

Nina Oestreicher

Deepa Lalla

Rowan T Chlebowski

Affiliations

Soon will be listed here.

Abstract

Purpose: Clinical outcomes have improved for women with early stage, HER2-positive breast cancer following the FDA approval of adjuvant trastuzumab use in 2006. However, only limited information exists on such patients' outcomes in real-world settings outside of clinical trials. We examined the risk of subsequent breast cancer in women with HER-2 positive disease, and the impact of trastuzumab use, in a large California community-based health plan.

Patients And Methods: A cohort of 3550 women with HER2-positive breast cancer (stages I-III) from 2009-2017 were followed through December 2018. We calculated subsequent breast cancer (SBC) rates overall and by trastuzumab use. Multivariable Cox proportional hazards modeling was used to compute hazard ratios (HR) and 95% confidence intervals (CI) for SBC by trastuzumab use.

Results: Within the cohort diagnosed with HER2-positive disease, 81% received adjuvant trastuzumab. After 4.1 mean years follow-up (maximum 10 years), the risk of SBC was 22% lower with adjuvant trastuzumab use (hazard ratio [HR] = 0.78, 95% confidence interval [CI]: 0.66-0.92) compared with non-use. The cumulative incidence of SBC precipitously rose two years after diagnosis and by the 10th year, the cumulative incidence was 31% among those who had trastuzumab therapy versus 34% without this therapy.

Conclusion: In community practice settings, the cumulative incidence of SBC in patients with early stage HER2-positive BC was 31% at 10 years in a cohort treated with adjuvant trastuzumab. Trastuzumab use was associated with a 22% reduced risk of developing SBC. This residual disease burden suggests breast cancer outcomes may be improved with further treatment given the advent of next-generation HER2-targeted therapies.

References

Chumsri S, Li Z, Serie D, Mashadi-Hossein A, Colon-Otero G, Song N . Incidence of Late Relapses in Patients With HER2-Positive Breast Cancer Receiving Adjuvant Trastuzumab: Combined Analysis of NCCTG N9831 (Alliance) and NRG Oncology/NSABP B-31. J Clin Oncol. 2019; 37(35):3425-3435. PMC: 6900835. DOI: 10.1200/JCO.19.00443. View

Slamon D, Clark G, Wong S, Levin W, Ullrich A, McGuire W . Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987; 235(4785):177-82. DOI: 10.1126/science.3798106. View

Haque R, Shi J, Schottinger J, Ahmed S, Chung J, Avila C . A hybrid approach to identify subsequent breast cancer using pathology and automated health information data. Med Care. 2015; 53(4):380-5. DOI: 10.1097/MLR.0000000000000327. View

Howie L, Scher N, Amiri-Kordestani L, Zhang L, King-Kallimanis B, Choudhry Y . FDA Approval Summary: Pertuzumab for Adjuvant Treatment of HER2-Positive Early Breast Cancer. Clin Cancer Res. 2018; 25(10):2949-2955. DOI: 10.1158/1078-0432.CCR-18-3003. View

Martin M, Holmes F, Ejlertsen B, Delaloge S, Moy B, Iwata H . Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2017; 18(12):1688-1700. DOI: 10.1016/S1470-2045(17)30717-9. View

von Minckwitz G, Procter M, de Azambuja E, Zardavas D, Benyunes M, Viale G . Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer. N Engl J Med. 2017; 377(2):122-131. PMC: 5538020. DOI: 10.1056/NEJMoa1703643. View

Chen F, Breiman R, Farley M, Plikaytis B, Deaver K, Cetron M . Geocoding and linking data from population-based surveillance and the US Census to evaluate the impact of median household income on the epidemiology of invasive Streptococcus pneumoniae infections. Am J Epidemiol. 1998; 148(12):1212-8. DOI: 10.1093/oxfordjournals.aje.a009611. View

Bonifazi M, Franchi M, Rossi M, Zambelli A, Moja L, Zambon A . Long term survival of HER2-positive early breast cancer treated with trastuzumab-based adjuvant regimen: a large cohort study from clinical practice. Breast. 2014; 23(5):573-8. DOI: 10.1016/j.breast.2014.05.022. View

Romond E, Perez E, Bryant J, Suman V, Geyer Jr C, Davidson N . Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005; 353(16):1673-84. DOI: 10.1056/NEJMoa052122. View

10.

Teerenhovi H, Tuominen S, Nurmi-Rantala S, Hemmila P, Ellonen A . Real-World Clinical Outcomes in Biological Subgroups of Breast Cancer in the Hospital District of Southwest Finland. Oncologist. 2021; 26(8):e1372-e1380. PMC: 8342560. DOI: 10.1002/onco.13813. View

11.

Cameron D, Piccart-Gebhart M, Gelber R, Procter M, Goldhirsch A, de Azambuja E . 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial. Lancet. 2017; 389(10075):1195-1205. PMC: 5465633. DOI: 10.1016/S0140-6736(16)32616-2. View

12.

Perez E, Romond E, Suman V, Jeong J, Sledge G, Geyer Jr C . Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831. J Clin Oncol. 2014; 32(33):3744-52. PMC: 4226805. DOI: 10.1200/JCO.2014.55.5730. View

13.

Schneeweiss A, Chia S, Hickish T, Harvey V, Eniu A, Hegg R . Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). Ann Oncol. 2013; 24(9):2278-84. DOI: 10.1093/annonc/mdt182. View

14.

Goldhirsch A, Gelber R, Piccart-Gebhart M, de Azambuja E, Procter M, Suter T . 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial. Lancet. 2013; 382(9897):1021-8. DOI: 10.1016/S0140-6736(13)61094-6. View

15.

Gianni L, Pienkowski T, Im Y, Roman L, Tseng L, Liu M . Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol. 2011; 13(1):25-32. DOI: 10.1016/S1470-2045(11)70336-9. View

16.

Piccart M, Procter M, Fumagalli D, de Azambuja E, Clark E, Ewer M . Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer in the APHINITY Trial: 6 Years' Follow-Up. J Clin Oncol. 2021; 39(13):1448-1457. DOI: 10.1200/JCO.20.01204. View

17.

Hortobagyi G . Trastuzumab in the treatment of breast cancer. N Engl J Med. 2005; 353(16):1734-6. DOI: 10.1056/NEJMe058196. View

18.

von Minckwitz G, Huang C, Mano M, Loibl S, Mamounas E, Untch M . Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer. N Engl J Med. 2018; 380(7):617-628. DOI: 10.1056/NEJMoa1814017. View

19.

Swain S, Baselga J, Kim S, Ro J, Semiglazov V, Campone M . Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med. 2015; 372(8):724-34. PMC: 5584549. DOI: 10.1056/NEJMoa1413513. View

20.

Barcenas C, Hurvitz S, Di Palma J, Bose R, Chien A, Iannotti N . Improved tolerability of neratinib in patients with HER2-positive early-stage breast cancer: the CONTROL trial. Ann Oncol. 2020; 31(9):1223-1230. DOI: 10.1016/j.annonc.2020.05.012. View